• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Warburg Pincus completes Lifecore offer

Article

According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.

New York-According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.

The offer, which was worth $17 per share or about $229.5 million, concluded with about 94.2% of outstanding Lifecore shares tendered.

Investments in health care-related companies around the world add up to $6.2 billion for Warburg Pincus, according to the private equity firm, including $2.7 billion in medical device makers such as American Medical Systems, Bausch & Lomb, ev3, Kyphon, Tornier, and Wright Medical Group.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.